Search

Displaying results 3721 - 3730 of 10000 in total
  1. Drug

    Etorphine

    go.drugbank.com/drugs/DB01497
    ExperimentalIllicitVet approved

    A narcotic analgesic morphinan used as a sedative in veterinary practice. … In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.

  2. Drug

    Dinitrochlorobenzene

    go.drugbank.com/drugs/DB11831
    Investigational

    Dinitrochlorobenzene has been used in trials studying the treatment of HIV Infections.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Canfosfamide

    go.drugbank.com/drugs/DB04972
    Investigational

    Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.

  4. Drug

    Berberine

    go.drugbank.com/drugs/DB04115
    ApprovedInvestigationalWithdrawn

    An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants.

  5. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  6. Drug

    EA-230

    go.drugbank.com/drugs/DB19114
    Investigational

    EA-230 is under investigation in clinical trial NCT03145220 (Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)).

  7. Drug

    Sarracenia Purpurea

    go.drugbank.com/drugs/DB13965
    ApprovedWithdrawn

    Cytoprotection in an in vitro model of diabetic neuropathy has also been studied. However, the use of Sarracenia Purpurea extracts in the clinical setting are limited. … It was used as an injectable pain reliever and during the 19th century, _Sarracenia purpurea_ was used as a treatment of smallpox [A32509].

  8. Drug

    GTI-2501

    go.drugbank.com/drugs/DB05406
    Experimental

    GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. … The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.

  9. Drug

    Tedizolid phosphate

    go.drugbank.com/drugs/DB09042
    Approved

    This product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).

  10. Drug

    Lexibulin

    go.drugbank.com/drugs/DB05147
    Investigational

    CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias